Advanced in Cerebral Hypoxia

Dr. Ricardo Restrepo-Jaramillo

Pulmonary Medicine | Intensive Care Medicine
University Medical Service Association Inc
3500 E Fletcher Ave, Suite 100, 
Tampa, FL 
Accepting New Patients
Advanced in Cerebral Hypoxia
University Medical Service Association Inc
3500 E Fletcher Ave, Suite 100, 
Tampa, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ricardo Restrepo-Jaramillo is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Tampa, Florida. Dr. Restrepo-Jaramillo is rated as an Advanced provider by MediFind in the treatment of Cerebral Hypoxia. His top areas of expertise are Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Interstitial Lung Disease, Cerebral Hypoxia, and Advanced Bronchoscopy. Dr. Restrepo-Jaramillo is currently accepting new patients.

His clinical research consists of co-authoring 14 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Cerebral Hypoxia.

Specialties
Pulmonary Medicine
Intensive Care Medicine
Licenses
Internal Medicine in FL
Hospital Affiliations
Sarasota Memorial Hospital
Tampa General Hospital
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Florida Blue
  • EPO
  • PPO
Freedom Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 18 Less Insurance Carriers -

Locations

UNIVERSITY MEDICAL SERVICE ASSOCIATION INC
3500 E Fletcher Ave, Suite 100, Tampa, FL 33613

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

ADAPT - A Patient Registry of the Real-world Use of Orenitram®
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
Enrollment Status: Active_not_recruiting
Publish Date: March 28, 2025
Intervention Type: Drug
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Biological
Study Drug: Sotatercept
Study Phase: Phase 3
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Enrollment Status: Terminated
Publish Date: November 24, 2023
Intervention Type: Drug
Study Drug: Inhaled treprostinil solution
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by CPET in Subjects With WHO Group 1 Pulmonary Hypertension Who Recently Initiated Therapy
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by CPET in Subjects With WHO Group 1 Pulmonary Hypertension Who Recently Initiated Therapy
Enrollment Status: Terminated
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Terminated
Publish Date: November 10, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
Enrollment Status: Terminated
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

14 Total Publications

BREEZE Optional Extension Phase: Long-term safety and efficacy of treprostinil dry powder inhaler (Tyvaso DPI) in pulmonary arterial hypertension.
BREEZE Optional Extension Phase: Long-term safety and efficacy of treprostinil dry powder inhaler (Tyvaso DPI) in pulmonary arterial hypertension.
Journal: Respiratory medicine
Published: June 18, 2025
Similar Doctors
Distinguished in Cerebral Hypoxia
Dr. Domenick J. Sorresso
Pulmonary Medicine
Distinguished in Cerebral Hypoxia
Dr. Domenick J. Sorresso
Pulmonary Medicine

C And D Pulmonary, P.A.

7614 Jacque Rd, Suite C, 
Hudson, FL 
 (25.8 miles away)
727-857-5967
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Domenick Sorresso is a Pulmonary Medicine provider in Hudson, Florida. Dr. Sorresso is rated as a Distinguished provider by MediFind in the treatment of Cerebral Hypoxia. His top areas of expertise are Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Cerebral Hypoxia, Gastrostomy, and Advanced Bronchoscopy. Dr. Sorresso is currently accepting new patients.

Distinguished in Cerebral Hypoxia
Dr. Perwaiz H. Rahim
Pulmonary Medicine | Sleep Medicine | Intensive Care Medicine
Distinguished in Cerebral Hypoxia
Dr. Perwaiz H. Rahim
Pulmonary Medicine | Sleep Medicine | Intensive Care Medicine
4712 Exploration Ave, 
Lakeland, FL 
 (32.8 miles away)
863-534-3707
Languages Spoken:
English, Urdu
See accepted insurances
Accepting New Patients

Perwaiz Rahim is a Pulmonary Medicine specialist and a Sleep Medicine provider in Lakeland, Florida. Dr. Rahim is rated as a Distinguished provider by MediFind in the treatment of Cerebral Hypoxia. His top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Atypical Pneumonia, Lung Metastases, and Hospital-Acquired Pneumonia. Dr. Rahim is currently accepting new patients.

Advanced in Cerebral Hypoxia
Dr. Ivan F. Ackerman
Pulmonary Medicine | Sleep Medicine
Advanced in Cerebral Hypoxia
Dr. Ivan F. Ackerman
Pulmonary Medicine | Sleep Medicine

Tampa Bay Pulmonary Medicine, PA

402 Noland Dr, 
Brandon, FL 
 (12.3 miles away)
813-655-2500
Languages Spoken:
English, French, Latin, Spanish
See accepted insurances
Accepting New Patients

Ivan Ackerman is a Pulmonary Medicine specialist and a Sleep Medicine provider in Brandon, Florida. Dr. Ackerman is rated as a Distinguished provider by MediFind in the treatment of Cerebral Hypoxia. His top areas of expertise are Lung Nodules, Lung Metastases, Drowsiness, and Excessive Daytime Sleepiness. Dr. Ackerman is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Restrepo-Jaramillo's expertise for a condition
ConditionClose
View All 13 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile